Skip to main content
Clinical Trials/NCT04328532
NCT04328532
Recruiting
Not Applicable

MRI Screening of Placenta Adhesion Abnormalities

Central Hospital, Nancy, France1 site in 1 country71 target enrollmentOctober 21, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Placenta; Implantation
Sponsor
Central Hospital, Nancy, France
Enrollment
71
Locations
1
Primary Endpoint
Area under the ROC curve of the T2* relaxation time mean value
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Placenta Adhesion Abnormalities (PAA) are the consequence of an excessive invasion of the placenta within the myometrium. PAA are related to severe maternal pregnancy outcomes, especially in case of incidental discovery during delivery that increase the risk of intraoperative massive bleeding, hysterectomy and even maternal death. Ultrasound is the standard modality for diagnosing PAA, but Magnetic Resonance Imaging (MRI) has been increasingly performed in the case of inconclusive sonographic findings. However, standard morphological MRI sequences appear as insufficient to improve the sensitivity and specificity values for detecting PAA, while quantitative MRI may be more efficient.

The main objective of this study is to characterize the diagnostic performance of quantitative MRI parameters (mainly Apparent Diffusion Coefficient, T2 and T2*) reflecting placental perfusion and/or oxygenation at high field, without injection of gadolinium-based agent, for the detection of PAA in women with ongoing pregnancy between 30 and 38 weeks of gestation with risk factors for PPA.

Registry
clinicaltrials.gov
Start Date
October 21, 2020
End Date
October 21, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Sponsor
Central Hospital, Nancy, France
Responsible Party
Principal Investigator
Principal Investigator

BERTHOLDT Charline

Doctor

Central Hospital, Nancy, France

Eligibility Criteria

Inclusion Criteria

  • Pregnant participant between 30 and 38 weeks of gestation,
  • Age ≥18 years old,
  • Participant who completed the preliminary medical examination,
  • Participant who has received full information about the organization of the research and has signed her informed consent.
  • Participant planning to give birth at CHRU of Nancy
  • Participant presenting risk factors for PAA : low-lying or covering placenta or in front of the uterine scar.

Exclusion Criteria

  • Multiple pregnancy,
  • Participant presenting at least one contraindication or restriction to performing an MRI as described in the protocol, in accordance with the current recommendations,
  • Participant unable to understand or follow study procedure,
  • Person referred to in Articles L. 1121-6 to L. 1121-8, L1122-2 and L. 1122-1-2 of the Public Health Code.

Outcomes

Primary Outcomes

Area under the ROC curve of the T2* relaxation time mean value

Time Frame: Through study completion, an average of 6 months

Area under the ROC curve of the T2 relaxation time mean value

Time Frame: Through study completion, an average of 6 months

Area under the ROC curve of the Apparent Diffusion Coefficient mean value

Time Frame: Through study completion, an average of 6 months

Study Sites (1)

Loading locations...

Similar Trials